The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

9 Oct 2013 07:00

RNS Number : 0482Q
Byotrol PLC
09 October 2013
 



9 October 2013

Byotrol plc

 

Board Changes

 

Byotrol plc ('Byotrol' or the "Company"), the developer of anti-microbial hygiene technologies, announces the appointment of David Traynor as Director and Chief Executive with immediate effect. Gary Millar has left the board to pursue other interests.

 

David has been Managing Director of Byotrol Consumer Products Limited ("BCP") since early 2012 and was previously a partner of WhatIf Joint Ventures Ltd ("WhatIf"), Byotrol's joint venture partner in BCP, since 2004. David worked in investment banking in the 15 years prior to joining WhatIf.

 

As announced on 3 October, completion of the acquisition of the shares in BCP that Byotrol does not already own will take place later today.

 

Following completion of the acquisition, Mr Traynor will hold 4,280,001 Ordinary Shares in Byotrol equating to 2.33 per cent. of the Company's issued share capital.

 

Commenting on the appointment, Ralph Kugler, Chairman of Byotrol, said:

 

"We are delighted to welcome David as the new Chief Executive of Byotrol plc. He has an excellent track record of driving product development and sales initiatives in consumer product environments which will help Byotrol achieve its goals. We thank Gary for his valuable contribution and wish him well for the future."

 

The following further information in relation to the appointment of Mr. Traynor is disclosed in accordance with Schedule 2(g) of the AIM Rules for Companies.

 

Full name: David Thomas Traynor

Age: 48

 

Current Directorships and Partnerships

Directorships and Partnerships held in the last five years

Byotrol Consumer Products Ltd

 

What If Innovation Capital Nominees Ltd

What If Joint Ventures Ltd

Irrigo Ltd

 

 

 

 

There are no other matters which are required to be announced pursuant to Schedule 2(g) of the AIM Rules for Companies.

 

Enquiries:

 

Byotrol plc

01925 742000

Ralph Kugler, Chairman

 

David Traynor, Chief Executive

 

Duncan Grosvenor, Finance Director

 

 

 

finnCap Limited

020 7220 0500

Nominated Adviser and broker

 

Geoff Nash/Christopher Raggett

Simon Starr (Corporate Broking)

 

 

 

Winningtons

020 3176 4722

Tom Cooper / Paul Vann

0797 122 1972

 

tom.cooper@winningtons.co.uk

 

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a leading anti-microbial technology hygiene company, operating globally in the Health, Food, Leisure, Consumer, Industrial and Agriculture sectors, providing a low toxicity product with a broad-based and long lasting efficacy across all microbial classes; bacteria, viruses, fungi, moulds and algae.

 

The Byotrol product can be used as a stand alone product or as a complementary biocide additive to existing products to improve their performance in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Founded in 2005, the Company has prioritised the development of a technology that creates easier, safer and cleaner lives through partnering with providers of essential goods and services. Byotrol is the catalyst behind the aptly named global 'Hygiene Revolution'.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAEANEPELKDFFF
Date   Source Headline
30th Apr 20247:00 amRNSCancellation - Byotrol Plc
29th Apr 20242:15 pmRNSSecondary Trading on Asset Match
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.